Have a feature idea you'd love to see implemented?
Let us know!
AMPH Amphastar Pharmaceuticals Inc
Price (delayed)
$49.63
Market cap
$2.42B
P/E Ratio
14.47
Dividend/share
N/A
EPS
$3.43
Enterprise value
$2.85B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
Amphastar Pharmaceuticals's quick ratio has surged by 136% YoY and by 52% QoQ
The stock's P/E is 84% less than its 5-year quarterly average of 88.1 and 9% less than its last 4 quarters average of 15.9
AMPH's debt is up by 17% year-on-year
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
48.68M
Market cap
$2.42B
Enterprise value
$2.85B
Price to earnings (P/E)
14.47
Price to book (P/B)
3.4
Price to sales (P/S)
3.4
EV/EBIT
11.76
EV/EBITDA
10.44
EV/Sales
3.99
Revenue
$712.89M
EBIT
$242.01M
EBITDA
$272.76M
Free cash flow
$178.13M
Per share
Balance sheet
Liquidity
EPS
$3.43
Free cash flow per share
$3.64
Book value per share
$14.59
Revenue per share
$14.58
TBVPS
$18.21
Total assets
$1.49B
Total liabilities
$778.18M
Debt
$620.58M
Equity
$713.35M
Working capital
$345.67M
Debt to equity
0.87
Current ratio
3.52
Quick ratio
2.57
Net debt/EBITDA
1.58
Margins
Efficiency
Dividend
EBITDA margin
38.3%
Gross margin
54.7%
Net margin
23.4%
Operating margin
32.2%
Return on assets
10.9%
Return on equity
25.4%
Return on invested capital
21.3%
Return on capital employed
17.9%
Return on sales
33.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-0.4%
1 week
-0.16%
1 month
4.73%
1 year
9.44%
YTD
-19.76%
QTD
2.27%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$712.89M
Gross profit
$389.81M
Operating income
$229.89M
Net income
$166.52M
Gross margin
54.7%
Net margin
23.4%
The operating income has surged by 75% year-on-year and by 9% since the previous quarter
The net income has soared by 63% YoY and by 8% from the previous quarter
The company's gross profit rose by 41% YoY and by 6% QoQ
AMPH's operating margin is up by 33% year-on-year and by 2.9% since the previous quarter
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
14.47
P/B
3.4
P/S
3.4
EV/EBIT
11.76
EV/EBITDA
10.44
EV/Sales
3.99
The stock's P/E is 84% less than its 5-year quarterly average of 88.1 and 9% less than its last 4 quarters average of 15.9
The EPS has soared by 63% YoY and by 7% from the previous quarter
Amphastar Pharmaceuticals's equity has increased by 21% YoY and by 6% from the previous quarter
The price to book (P/B) is 17% higher than the 5-year quarterly average of 2.9 but 6% lower than the last 4 quarters average of 3.6
Amphastar Pharmaceuticals's revenue has increased by 32% YoY and by 5% QoQ
AMPH's price to sales (P/S) is 10% more than its 5-year quarterly average of 3.1 but 6% less than its last 4 quarters average of 3.6
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROS has grown by 37% YoY and by 4.6% from the previous quarter
The ROE has grown by 35% YoY and by 2.4% from the previous quarter
The company's return on assets rose by 6% QoQ but it fell by 3.5% YoY
The ROIC is up by 2.9% since the previous quarter
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 92% greater than the total liabilities
Amphastar Pharmaceuticals's quick ratio has surged by 136% YoY and by 52% QoQ
Amphastar Pharmaceuticals's current ratio has soared by 130% YoY and by 61% from the previous quarter
AMPH's debt is 13% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 21% YoY and by 6% from the previous quarter
AMPH's debt is up by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.